CGM Lead Generation for Continuous Glucose Monitor Campaigns

Continuous glucose monitors have changed diabetes care, and Medicare has expanded coverage to match. AnJaanX generates prequalified CGM leads screened against Medicare eligibility criteria, built on documented consent and honest qualification, for DME suppliers and distributors running CGM programs.

The CGM market is growing fast: global device sales are projected to roughly double over the next decade as diabetes prevalence climbs and sensors get smaller, cheaper, and more accurate. But CGM is also one of the most abused categories in DME marketing, because the devices are desirable and the eligibility rules are specific. Leads generated without screening produce patients who want a CGM but cannot get one covered, which means shipped devices, denied claims, and audit risk. Qualification is the whole game.

Medicare CGM Coverage: What the Rules Actually Say

Medicare covers therapeutic CGM for beneficiaries who meet its criteria. The core requirements center on insulin use and testing frequency: the patient is insulin-treated, tests blood glucose frequently, and has a documented need for a CGM to manage their diabetes, with an in-person physician visit supporting the order. Coverage details and local coverage determinations evolve, so screening must track current policy, not last year's version.

Our qualification flow checks the practical proxies for these rules before a lead is delivered: diabetes diagnosis type, insulin regimen, current testing routine, and an existing relationship with a treating physician who can document the order. Prospects who do not meet the criteria are not sold to you. They are filtered out.

How We Qualify a CGM Lead

• Diabetes and treatment profile: type 1 or insulin-treated type 2 diabetes, current insulin use, and testing frequency that supports medical necessity.
• Medicare Part B status: active Part B coverage confirmed, since CGM is a Part B DME benefit.
• Physician relationship: a treating doctor is identified who can conduct the required visit and sign the order.
• Identity verification: SNS-level identity screening so the person on the file is the person on the phone.
• Consent documentation: clear, documented opt-in for contact about CGM options, naming the seller.

This is the same verification discipline we apply across our DME lead generation programs, adapted to CGM's specific coverage rules.

Why CGM Campaigns Fail Without Screening

The failure mode is always the same: a vendor sells volume, the supplier ships to patients whose coverage or documentation cannot support the claim, and the denial rate destroys the unit economics. CGM devices and sensors are expensive inventory to place with an unqualified patient. A smaller number of genuinely qualified leads consistently outperforms a large file of hopeful ones, because every downstream cost, shipping, onboarding, documentation chase, and appeals work, multiplies on bad leads and disappears on good ones.

Compliance in CGM Marketing

Three rules govern this space. First, the FCC's one-to-one consent requirement: telemarketing contact needs prior express written consent naming the specific seller, with clear disclosures. Second, CMS marketing rules restrict how beneficiary data moves between marketing organizations. Third, marketing copy must not promise medical outcomes or imply coverage that is not there. Our scripts describe CGM factually, document consent, and let physicians and coverage rules determine who qualifies.

Built for DME Operators

CGM programs run best alongside complementary lines: BGM leads for patients who test with traditional meters, Medicare live transfers for real-time enrollment conversations, and medical billing outsourcing to keep the back end clean once volume grows. One compliance infrastructure, one qualification standard, multiple revenue lines.

Frequently Asked Questions